MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/2162402x.2018.1512329

Медицинская библиотека · Oncoimmunology · 2018

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol Jonathan G, Acuna Sergio A, Yadollahi Beta, Tang Nan, Stephenson Kyle B, Atherton Matthew J, Hanwell David, El-Warrak Alexander, Goldstein Alyssa, Moloo Badru, Turner Patricia V, Lopez Roberto, LaFrance Sandra, Evelegh Carole, Denisova Galina, Parsons Robin, Millar Jamie, Stoll Gautier, Martin Chantal G, Pomoransky Julia, Breitbach Caroline J, Bramson Jonathan L, Bell John C, Wan Yonghong, Stojdl David F, Lichty Brian D, McCart J Andrea

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (Macaca fascicularis). Primates received a replication-deficient adenoviral prime, boosted by the oncolytic Maraba MG1 rhabdovirus. Both vectors expressed the human MAGE-A3. No severe adverse events were observed. Boosting with MG1-MAGEA3 induced an expansion of hMAGE-A3-specific CD4+ and CD8+ T-cells with the latter peaking at remarkable levels and persisting for several months. T-cells reacting against epitopes fully conserved between simian and human MAGE-A3 were identified. Humoral immunity was demonstrated by the detection of circulating MAGE-A3 antibodies. These preclinical data establish the capacity for the Ad:MG1 vaccination to engage multiple effector immune cell populations without causing significant toxicity in outbred NHPs. Clinical investigations utilizing this program for the treatment of MAGE-A3-positive solid malignancies are underway (NCT02285816, NCT02879760).

Для цитирования: Pol Jonathan G, Acuna Sergio A, Yadollahi Beta, Tang Nan, Stephenson Kyle B, Atherton Matthew J, Hanwell David, El-Warrak Alexander, Goldstein Alyssa, Moloo Badru, Turner Patricia V, Lopez Roberto, LaFrance Sandra, Evelegh Carole, Denisova Galina, Parsons Robin, Millar Jamie, Stoll Gautier, Martin Chantal G, Pomoransky Julia, Breitbach Caroline J, Bramson Jonathan L, Bell John C, Wan Yonghong, Stojdl David F, Lichty Brian D, McCart J Andrea. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.. Oncoimmunology. 2018. DOI: 10.1080/2162402x.2018.1512329.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.